CAS: 304000-05-3
| Marke | Produktdaten | Reinheit | Preisklasse | Voraussichtliche Lieferung |
|---|---|---|---|---|
 | (4E)-2-(3,4-dimethoxyphenyl)-4-[(pyridin-3-yl)methylidene]-4,5-dihydro-1,3-oxazol-5-one REF: IN-DA01WAUCCAS: 304000-05-3 | 98% | Nachfragen | Do 14 Nov 24 |
 | DAPK-IN-2 REF: TM-T77611CAS: 304000-05-3 | 98.26% | 91,00 €~2.009,00 € | Fr 15 Nov 24 |
![(4E)-2-(3,4-dimethoxyphenyl)-4-[(pyridin-3-yl)methylidene]-4,5-dihydro-1,3-oxazol-5-one](https://static.cymitquimica.com/products/IN/thumb/DA01WAUC.jpg)
(4E)-2-(3,4-dimethoxyphenyl)-4-[(pyridin-3-yl)methylidene]-4,5-dihydro-1,3-oxazol-5-one
CAS:304000-05-3
Formel:
C17H14N2O4
Reinheit:
98%
Molekulargewicht:
310.3041
Ref: IN-DA01WAUC
| 5mg | 145,00 € | ||
| 10mg | 243,00 € | ||
| 25mg | 547,00 € | ||
| 50mg | Nachfragen | ||
| 100mg | Nachfragen |
Voraussichtliche Lieferung in Vereinigte Staaten, am Donnerstag 14. November 2024
DAPK-IN-2
CAS:304000-05-3
DAPK-IN-2: DAPK inhibitor with anticancer potential. Used in cerebral infarction and ischemia research.
Formel:
C17H14N2O4
Reinheit:
98.26%
Farbe und Form:
Liquid
Molekulargewicht:
310.3
Ref: TM-T77611
| 1mg | 91,00 € | ||
| 2mg | 134,00 € | ||
| 5mg | 215,00 € | ||
| 10mg | 335,00 € | ||
| 25mg | 558,00 € | ||
| 50mg | 742,00 € | ||
| 100mg | 1.009,00 € | ||
| 500mg | 2.009,00 € |
Voraussichtliche Lieferung in Vereinigte Staaten, am Freitag 15. November 2024
